Evidence map›Paper›PMID 39597986›Full record

ReviewJournal of clinical medicine2024

Urgent Reversal of Direct Oral Anticoagulants in Critical and Life-Threatening Bleeding: A Multidisciplinary Expert Consensus.

Anabela Rodrigues, Luciana Ricca Gonçalves, Tiago Gregório, Cilénia Baldaia, Gustavo C Santo, João Gouveia

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anabela RodriguesServiço de Imuno-Hemoterapia, Unidade Local de Saúde (ULS) Santa Maria, 1649-028 Lisboa, Portugal.ORCID 0000-0001-9981-030X
Luciana Ricca GonçalvesServiço de Imuno-Hemoterapia, Unidade Local de Saúde (ULS) São João, 4200-319 Porto, Portugal.
Tiago GregórioServiço de Medicina Interna e Unidade AVC, Unidade Local de Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal.ORCID 0000-0002-0131-9430
Cilénia BaldaiaServiço de Medicina Intensiva, Unidade Local de Saúde (ULS) Santa Maria, 1649-028 Lisboa, Portugal.
Gustavo C SantoServiço de Neurologia, Hospitais da Universidade de Coimbra, Unidade Local de Saúde (ULS) de Coimbra, 3004-561 Coimbra, Portugal.
João GouveiaServiço de Medicina Intensiva, Unidade Local de Saúde (ULS) Santa Maria, 1649-028 Lisboa, Portugal.

Funding

AstraZeneca (Portugal)
6 · The paper itself

Abstract

Direct oral anticoagulants (DOACs) are increasingly being used due to their improved efficacy/safety ratio and lower clinical and economic burden when compared to vitamin K antagonists. However, bleeding is still the most frequent complication associated with DOACs, and although rare, bleeding episodes can be life-threatening or critical. The impact of DOAC anticoagulation activity during a bleeding event must be evaluated according to patient clinical assessment, dosage and time from last intake, the presence of comorbidities (especially kidney and liver dysfunction), and, whenever possible, coagulation tests. Unfortunately, DOACs' anticoagulation activity is not easily or usually detectable in routine common coagulation testing. Specific DOAC tests allow for specific drug monitoring, but they are too time consuming, and are usually unavailable in routine emergency practice. If a clinically relevant DOAC plasma concentration is assumed or proven in a severe bleeding scenario, DOAC reversal is needed to restore hemostasis. This experts' consensus provides a narrative review about DOAC reversal and practical life-threatening bleeding management in several scenarios (trauma, intracranial hemorrhage and gastrointestinal bleeding), focusing on the selection of patients to whom specific reversal agents should be given.

Indexed as

bleedingcriticaldirect oral anticoagulantdirect thrombin inhibitorFXa inhibitorsgastrointestinal bleedingintracranial hemorrhagelife threateningreversaltrauma

Identifiers

PMID39597986
PMCPMC11595216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.